Creo Medical Group (LON:CREO) Share Price Passes Below 50 Day Moving Average – What’s Next?

Creo Medical Group PLC (LON:CREO)’s share price crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 13.44 and traded as low as GBX 12.75. Creo Medical Group shares last traded at GBX 12.77, with a volume of 458,074 shares trading hands.

Wall Street Analyst Weigh In

Separately, Shore Capital Group reaffirmed a “house stock” rating and issued a GBX 40 price objective on shares of Creo Medical Group in a research note on Thursday, July 23rd.

Creo Medical Group Stock Performance

The company has a market capitalization of £63.15 million, a P/E ratio of 13.00 and a beta of 1.56. The business has a 50-day moving average of GBX 13.43 and a 200-day moving average of GBX 13.24. The company has a debt-to-equity ratio of 8.20, a current ratio of 3.22 and a quick ratio of 2.19.

Insider Buying and Selling at Creo Medical Group

In other news, insider Richard John Rees bought 6,250 shares of the stock in a transaction dated Wednesday, July 1st. The stock was purchased at an average price of GBX 14 per share, for a total transaction of £875. Also, insider Craig Jonathan Gulliford bought 6,250 shares of the stock in a transaction dated Wednesday, July 1st. The stock was purchased at an average price of GBX 14 per share, with a total value of £875. Corporate insiders own 7.00% of the company’s stock.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.